Stayble Therapeutics' injectable and lactic acid-based drug candidate STA363 triggers a connective tissue transformation in the spinal disc, which is expected to provide long-term pain relief for patients with discogenic chronic low back pain. BioStock deep dive into the benefits of STA363.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/10-advantages-of-staybles-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock--10-advantages-of-stayble-s-treatment,c3593178

(c) 2022 Cision. All rights reserved., source Press Releases - English